5 results about "Receptor specificity" patented technology

The present invention provides isolated T cell receptors (TCRs) that specifically bind to an HLA-displayed cancer testis antigen preferentially expressed antigen in melanoma (FRAME) peptide, as well as therapeutic and diagnostic methods of using those isolated TCRs.

This invention provides the application of cyperene in the preparation of olfactory receptor Olfr43 specific agonist drugs, relating to the field of small molecule pharmaceutical technology of traditional Chinese medicine. This invention constructs Hana3A... Olfr43‑FLuc‑RLuc A heterologous OR dual-luciferase screening platform revealed that cyperene can activate the downstream pathway of the olfactory receptor Olfr43, significantly increasing intracellular cAMP levels. Cellular experiments further verified that cyperene stimulation significantly increased the mNRA and protein expression levels of Olfr43 in cells, raising downstream cAMP levels. This, in turn, inhibited the expression of lipid synthesis-related genes by phosphorylating CREB, promoting HES-1, and inhibiting DGAT2 protein expression, ultimately reducing TC and TG in the HepG2 hyperlipidemia model. This invention is the first to propose that cyperene can act as a specific agonist targeting the olfactory receptor Olfr43 to regulate downstream cAMP changes. This invention provides a new option for the development of highly effective agonists specifically targeting Olfr43 / OR1A1.

Some embodiments of the methods and compositions provided herein include cells having membrane-tethered, IL13 mutein-directed zetakine receptors, such as those which specifically bind to the IL-13 receptor alpha 2 (IL13Ra2) at a 50-fold higher affinity than wildtype IL-13, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors, using these compositions. In some embodiments, the receptors include spacer regions, such as particular spacer regions designed to provide certain advantages.

Disclosed in the present invention are a synthetic T cell receptor antigen receptor specifically binding to LILRB4 and the use thereof. In the present invention, TCR and CAR are modified by means of targeting the antigen binding fragment of LILRB4, so that a better effect on tumor treatment is obtained.